Insulin Resistance, Obesity
Conditions
Keywords
Obesity, Insulin Resistance
Brief summary
This study is being done to better understand the relationship between inflammation and insulin resistance in your Adipose (fat) Tissue .
Detailed description
This study is being done to determine whether eosinophils (a type of white blood cell) play an important role in human fat metabolism and inflammation. This study is being done to determine if fish oil supplement could play a role in reducing inflammation and improving insulin sensitivity in your fat tissue.
Interventions
PROCEDUREFat biopsy during scheduled abdominal surgery
Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
PROCEDUREFat Aspiration
Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
DIETARY_SUPPLEMENTFish Oil Supplement
Fish Oil supplementation for three months.
Sponsors
Mayo Clinic
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Lean, healthy person with a body mass index (BMI) of 25 or less, or you are obese, BMI between 30 and 50, and non-diabetic. Lean healthy controls will not be on any medication and will be undergoing elective abdominal surgery excluding those involving acute inflammation (i.e. acute cholecystitis, bowel perforation, or diverticulitis). Obese, non-diabetic subjects will have a BMI between 30 and 50 and be taking no medications affecting glucose metabolism or lipid metabolism. These subjects will be identified from a pool of patients undergoing an elective abdominal surgical procedure such as inguinal hernia repair, laparoscopic Nissen fundoplication, planned cholecystectomy, but also bariatric surgery. Volunteers will not be taking corticosteroid therapy or have a history of asthma, COPD or atopic syndrome. All subjects will undergo a medical history intake and a physical examination followed by an OGTT to confirm normal glucose.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Eosinophil content in adipose tissue | baseline | Eosinophils number will be measured by flow cytometry in subcutaneous and visceral fat of lean vs obese, non-diabetic volunteers |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Relationship between eosinophils content and body mass index (BMI) | baseline | Measure as a linear regression between BMI (kg/m2) and eosinophils number in the fat |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in insulin sensitivity | Baseline, post fish oil supplementation (approximately 3 months) | Measured by euglycemic-hyperinsulinemic clamp taken before and after fish oil supplementation |
| Change in plasma inflammatory cytokines | Baseline, post fish oil supplementation (approximately 3 months) | Measured by Elisa reported in pg/mL before and after fish oil supplementation |
| Change in plasma inflammatory adipokines | Baseline, post fish oil supplementation (approximately 3 months) | Measured by Elisa reported in pg/mL before and after fish oil supplementation |
| Change in adipose tissue inflammatory markers | Baseline, post fish oil supplementation (approximately 3 months) | Measured by mRNA levels of pro-inflammatory markers before and after fish oil supplementation |
Countries
United States
Outcome results
None listed